LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21
LumiraDx Limited (Nasdaq: LMDX) plans to release its Q4 and full year 2022 financial results on March 21, 2023. A conference call will be held at 8:30 AM ET to discuss these results and business highlights. LumiraDx specializes in next-generation point of care diagnostics, utilizing microfluidic technology for quick, accessible testing solutions across various healthcare settings. The company offers over 30 assays for diseases such as infectious diseases, cardiovascular issues, and diabetes, reflecting a broad testing menu aimed at transforming community healthcare.
- None.
- None.
LONDON, March 14, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21st, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights.
| LumiraDx Fourth Quarter and Full Year 2022 Financial Results Conference Call | |
| Date: | Tuesday, March 21, 2023 |
| Time: | 8:30 AM Eastern Time |
| Live Call/Webcast: | Register to join by phone here. |
| View webcast: https://investors.lumiradx.com/news-and-events/investor-calendar |
A replay of the webcast will be available on the Investors section of the company's website at investors.lumiradx.com shortly after the conclusion of the call. The webcast will be archived for one year.
About LumiraDx
LumiraDx Limited (Nasdaq: LMDX) is a next-generation point of care diagnostics company that is transforming community-based healthcare. Its actively controlled microfluidic technology provides fast, high performance and accessible diagnostic solutions wherever the patient is for nearly any testing scenario, creating unique testing options at the point of need.
The company offers a broad menu of lab comparable tests on a single portable Platform, with more than 30 assays on the market and in the pipeline, covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. The company also supports high-complexity laboratory testing in an accessible high-throughput format to leverage current molecular laboratory operations.
Founded in 2014 and based in the UK, LumiraDx's diagnostic testing solutions are being deployed globally by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to help screen, diagnose, and monitor wellness as well as disease. More information on LumiraDx is available at www.lumiradx.com.
FAQ
When will LumiraDx release its Q4 and full year 2022 financial results?
What time will LumiraDx's conference call take place?
What is LumiraDx's main business focus?
How many assays does LumiraDx offer?
